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Abstract
Adenosine, a neuromodulator of the CNS, activates inhibitory-
A1 receptors and facilitatory-A2A receptors; its synaptic levels
are controlled by the activity of bi-directional equilibrative nu-
cleoside transporters. To study the relationship between the
extracellular formation/inactivation of adenosine and the acti-
vation of adenosine receptors, we investigated how A1 and
A2A receptor activation modifies adenosine transport in hip-
pocampal synaptosomes. The A2A receptor agonist, CGS
21680 (30 nM), facilitated adenosine uptake through a PKC-
dependent mechanism, but A1 receptor activation had no
effect. CGS 21680 (30 nM) also increased depolarization-in-
duced release of adenosine. Both effects were prevented by
A2A receptor blockade. A2A receptor-mediated enhancement
of adenosine transport system is important for formatting
adenosine neuromodulation according to the stimulation fre-
quency, as: (1) A1 receptor antagonist, DPCPX (250 nM),
facilitated the evoked release of [3H]acetylcholine under low-
frequency stimulation (2 Hz) from CA3 hippocampal slices,
but had no effect under high-frequency stimulation (50 Hz); (2)
either nucleoside transporter or A2A receptor blockade
revealed the facilitatory effect of DPCPX (250 nM) on
[3H]acetylcholine evoked-release triggered by high-frequency
stimulation. These results indicate that A2A receptor activation
facilitates the activity of nucleoside transporters, which have a
preponderant role in modulating the extracellular adenosine
levels available to activate A1 receptors.
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Adenosine is a modulator that exerts its action through four
types of metabotropic receptors – A1, A2A, A2B and A3
(Fredholm et al. 2001). In particular, the neuromodulatory
role of adenosine depends mostly on a balanced activation of
inhibitory A1 receptors and facilitatory A2A receptors (see
Sebastia˜o and Ribeiro 2000). There are two main sources of
extracellular adenosine in the nervous system: adenosine
release through bi-directional equilibrative nucleoside trans-
porters (ENTs) and extracellular conversion of adenine
nucleotides into adenosine by ecto-nucleotidases (for review
see Latini and Pedata 2001). Whereas ecto-nucleotidases can
only form adenosine, nucleoside transporters fulfil a dual
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role, because blockade of adenosine transport can inhibit
either adenosine release or adenosine uptake in the hippo-
campus, depending upon its intra- and extracellular levels
(Gu et al. 1995).
The activity of ENTs is controlled by G proteins (Sweeney
1996) and protein kinases (Sen et al. 1999). Adenosine
receptors, which are coupled to G proteins and protein
kinase-dependent transducing systems, appear therefore to be
good candidates to modify the levels of their endogenous
ligand, adenosine. It has been shown that A2 receptor
activation can increase adenosine uptake in chromaffin cells
(Delicado et al. 1990), an issue that remains to be confirmed
in neurones. This control of the levels of extracellular
adenosine by adenosine A2 receptors might be particularly
important in brain areas such as the hippocampus under high-
frequency neuronal firing, which favours the activation of
adenosine receptors of the A2A subtype (Cunha et al. 1996a),
as well as a predominant formation of extracellular adenosine
through the ecto-nucleotidase pathway (Cunha et al. 1996b).
Thus, we now directly tested if the activation of adenosine
A2A receptors could control the release and uptake of
adenosine through nucleoside transporters in hippocampal
preparations. This was tested in nerve terminals where ENTs
play an important role in the metabolism of adenosine (e.g.
Gu et al. 1995). Because it was previously shown that the
evoked release of acetylcholine (ACh) from rat hippocampal
slices is under the control of endogenous extracellular
adenosine operating mainly A1 receptors (Jackisch et al.
1984), but also A2A receptors (Cunha et al. 1994), the
modulation of electrically evoked [3H]ACh release by tonic
A1 receptor activation was subsequently used in the present
work as a ‘model’ to evaluate how the A2A receptor-mediated
enhancement of nucleoside transporters could affect tonic
neuromodulation by endogenous adenosine.
Materials and methods
Materials
4-(2-[7-Amino-2-(2-furyl) [1,2,4] triazolo [2,3-a] [1,3,5] triazin-
5-ylamino]ethyl)phenol (ZM 241385), 2-p-(2-carboxyethyl)pheneth-
ylamino-5¢-N-ethylcarboxamidoadenosine hydrochloride (CGS
21680) and 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-
yl)maleimide (GF-109203X) were purchased from Tocris Cookson
(Ballwin, MO, USA). N6-cyclopentyladenosine (CPA), 1,3-dipro-
pyl,8-cyclopentylxanthine (DPCPX), dipyridamol, hemicholinium-3
(HC-3), S-(p-nitrobenzyl)-6-thioinosine (NBTI), N6,2¢-o-dibutyry-
ladenosine-3¢,5¢-cyclic monophosphate sodium salt (dbcAMP),
N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide di-
hydrochloride (H-89), phorbol-12,13-didecanoate (PDD) and
adenosine were from Sigma (St Louis, MO, USA). 5-amino-7-
(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyr-
imidine (SCH 58261) was a gift from Dr Scott Weiss (Vernalis, UK).
[Methyl-3H]choline chloride (specific activity 76–86.3 Ci/mmol),
and [2–3H]adenosine (22–28 Ci/mmol) were obtained from Amer-
sham (Arlington Heights, IL, USA). DPCPX was made up as a 5-mM
stock solution in dimethylsulfoxide (DMSO) with 1% NaOH 1 M (v/
v). The following stock solutions were prepared in DMSO: CGS
21680 (5 mM), SCH 58261 (5 mM), CPA (5 mM), adenosine
(100 mM), dipyridamol (2.5 mM), NBTI (10 mM), PDD (5 mM),
GF-109203X (5 mM) and H-89 (5 mM). HC-3 (10 mM) and dbcAMP
(10 mM) were prepared in water. Aliquots of all stock solutions were
kept frozen at )20C until used.
Preparation of CA3 subslices and synaptosomes from rat
hippocampus
The experiments were performed on Wistar rats (6–8 weeks old)
from Harlan Interfauna Iberica, SL (Barcelona, Spain). The animals
were handled according to the European Community guidelines and
Portuguese law on Animal Care and were anaesthetized with
halothane before decapitation. The hippocampus was dissected free
within ice-cold Krebs’ solution of the following composition:
124 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 1 mM MgSO4, 2 mM
CaCl2, 26 mM NaHCO3 and 10 mM glucose, pH 7.4.
When preparing hippocampal slices, the hippocampi were
transversely cut 400 lm thick, the CA3 subslices manually
dissected and allowed to recover for 1 h in gassed Krebs solution
(95% O2 and 5% CO2) kept at room temperature (20–22C).
The synaptosomal P2 fraction and purified nerve terminals
(synaptosomes) were isolated as previously (e.g. Cunha et al. 2000).
[3H]Adenosine uptake assay
Synaptosomes were resuspended in 1 mL of Krebs/HEPES solution
with the following composition: NaCl 124 mM, KCl 3 mM,
NaH2PO4 1.25 mM, MgSO4 1 mM, CaCl2 2 mM, HEPES 26 mM,
glucose 10 mM, pH 7.4) and equilibrated at 37C. All adenosine
transport assays were conducted at 37C in a total volume of
300 lL, containing 150–200 lg of protein (see Cunha et al. 2000).
Transport was initiated by addition of 1 lM [3H]adenosine, added at
least 10 min after exposing synaptosomes to the tested drugs, and
was terminated 15 s after initiating its uptake by the addition of
5 mL of an ice-cold transport inhibitor mixture composed by
dipyridamol (20 lM), NBTI (10 lM) and adenosine (1 mM), in
Krebs/H followed by low-pressure filtration through 0.45-lm filters
(Millipore LCWP-047, Millipore Corporation, Bedford, MA, USA)
loaded in a Millipore holder. The reaction tube was washed off with
further 5 mL of the same solution. The filters were analysed by
liquid scintillation counting for determination of tritium retained by
synaptosomes after addition of 5 mL of scintillation cocktail
(Optiphase Hi-Safe 2, Perkin-Elmer, Foster City, CA, USA).
Adenosine transport was calculated as the difference between the
total amount of adenosine taken up by synaptosomes and the non-
specific component of [3H]adenosine fixation by synaptosomes,
determined in the presence of dipyridamol (20 lM), NBTI (10 lM)
and adenosine (1 mM).
Adenosine release experiments
Because considerable amounts of protein are required for these
assays, the P2 synaptosomal fraction was used. Perfusion chambers
(90 lL) fitted with Whatman (Brentford, Middlesex, U.K.) GF/C
filters were loaded with the synaptosomal fraction and a period of
45 min was allowed for equilibrium, before starting sample collec-
tion. Perfusion was at 0.6 mL/min with a 95% O2/5% CO2 gassed
Krebs solution at 32C throughout the experiment. Drugs were added
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10 min prior to starting sample collection, and were present onwards.
Synaptosomes were stimulated from minute 6 to minute 11 with a
high-K+ (28 mM) solution. Each individual experiment comprised a
control chamber and one different chamber for each drug condition.
The amount of adenosine in each collected sample (3 min) was
assessed after derivatization to N6-ethenoadenosine, and then
quantified by high-performance liquid chromatography [HPLC;
100 mM K2HPO4 in 15% (v/v) methanol/water, pH 6.5, 1.75 mL/
min flow rate] with fluorescence detection (see Zhang et al. 1991).
The retention time of N6-ethenoadenosine was of 2.9 min, identified
by comparison with an injection of a N6-ethenoadenosine standard.
All injections were performed in duplicate. Adenosine release evoked
by high-K+ stimulation, i.e. the evoked release (expressed in nmol/mg
protein), was calculated by integration of the area of the peak on
subtraction of the estimated basal outflow of endogenous adenosine,
with GraphPad Software (Prism, version 4.02 for Windows,
GraphPad Software Inc., San Diego, CA, USA).
[3H]Ach-evoked release experiments
The release of [3H]ACh from CA3 subslices was performed as
previously (e.g. Cunha et al. 1994). Briefly, after incubation with
[methyl-3H]choline (12.3 lCi/mL, 0.15 lM) for 30 min at 32C and
washout, the subslices were placed in 100 lL Perspex chambers
(three subslices per chamber) and superfused with gassed Krebs
solution at 32C (flow rate of 0.6 mL/min). From this moment
onwards hemicholinium-3 (10 lM) was present in all solutions used.
A washout period of 45–60 min was allowed before starting sample
(3 min) collection. The preparations were then stimulated at min 6
(S1) and at min 36 (S2) with supramaximal square-wave pulses
(1 ms, with an amplitude of approximately 15 V). Stimuli were
delivered either with low-frequency (LFS, 2 Hz for 2 min; total
number of pulses: 240) or with high-frequency (HFS, 50 Hz). HFS
paradigm consisted of four bursts (1.2 s each) of 60 pulses (total
number of pulses: 240), applied with 200 ms interburst periods,
except otherwise indicated.
Four perfusion chambers were used per experiment, two for
controls (absence of drugs, or same drugs during S1 and S2) and
two for test conditions (test drug before S2). When the effects of
either the A1 antagonist, DPCPX (250 nM), or the A1 agonist, CPA
(300 nM), were investigated, these test drugs were added to the
perfusion medium 21 min before S2, i.e. 15 min after starting
sample collection, and remained in the superfused solution up to
the end of the experiment. The effects of each of these test drugs
on the evoked release of [3H]ACh were expressed by changes of
the ratios between the evoked release in S2 (in the presence of the
drug) and the evoked release in S1 (in the absence of drugs; S2/S1
ratio), by comparison with the S2/S1 ratios obtained in control
conditions in the same experiment (i.e. in the absence of drugs).
When evaluating the effects of DPCPX (250 nM) in the presence
of the ENT inhibitor, NBTI (10 lM), or the A2A receptor
antagonist, SCH 58261 (250 nM), these drugs were applied
15 min before starting sample collection and were present in all
superfused solutions from that moment onwards; because both
stimulation periods were performed under the effects of those
drugs, the S2/S1 ratios remained virtually unaffected. In these
experiments, DPCPX (250 nM) was added to the superfused
conditions 15 min before S2, as before, and its effect expressed by
changes in the S2/S1 ratio, as compared it with the S2/S1 ratios
obtained in control conditions in the same experiments (i.e. in the
presence of either NBTI or SCH 58261).
At the end of the experiments the slices were homogenized
(sonicated in 500 lL of 3 M perchloric acid and 20% Triton X-100)
and sampled. All samples were analysed by scintillation counting.
The evoked release was calculated by integration of the area of the
peak on subtraction of the estimated basal tritium outflow from the
total outflow due to electrical stimulation. Field-electrically evoked
tritium outflow from hippocampal slices loaded with [3H]choline is
Ca2+-dependent and tetrodotoxin-sensitive (Fredholm and Du´ner-
Engstrom 1989) and is mainly due to [3H]ACh release (Cunha et al.
1994), which makes tritium quantification a good measure of the
evoked release of [3H]ACh.
Statistical analyses
Data are presented as the mean results ± SEM from n experiments.
When comparing two-groups of results, statistical significance was
assessed using Student’s t-test. When doing multiple comparisons,
statistical significance was assessed by one-way ANOVA followed by
the Bonferroni correction, using GraphPad Software (Prism, version
4.02 for Windows). Values of p < 0.05 were considered statistically
significant.
Results
Activation of A2A receptor enhances adenosine uptake
In the experiments evaluating adenosine uptake, [3H]adeno-
sine was applied at a concentration near the nucleoside
transporters Km value for adenosine, 1 lM, as first calculated
by Bender et al. (1981) for cortical synaptosomes, and found
to be similar for nucleoside transporters in the hippocampus
(Cunha et al. 2000). Thus, we compared the ability of
hippocampal nerve terminals to take up adenosine at a
concentration of 1 lM in the absence and in the presence of
the selective A2A receptor agonist CGS 21680. In a control
situation, synaptosomes incorporated 0.27 ± 0.06 pmol of
[3H]adenosine per mg of protein. As Fig. 1 shows, CGS
21680 (30 nM) significantly (p < 0.05) increased the uptake
of adenosine by 66 ± 17% (n ¼ 7). This CGS 21680-induced
enhancement of adenosine uptake was totally prevented by
the selective A2A receptor antagonist, SCH 58261 (250 nM,
n ¼ 7), which by itself did not appreciably modify
[3H]adenosine uptake. Activation of A1 receptors with the
selective A1 receptor agonist, CPA (100 nM), failed to modify
(n ¼ 7, p > 0.05) the uptake of [3H]adenosine (Fig. 1).
A2A receptor-mediated enhancement of adenosine uptake
occurs via PKC activation
It is consensual that pre-synaptic A2A receptor activation
triggers intracellular cAMP accumulation leading to the
subsequent activation of PKA. However, it is also accepted
that A2A receptors operate a parallel signalling transducing
mechanisms, via PKC activation (for review see Cunha
2001). Accordingly, we next investigated which intracellular
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messengers were involved in the A2A receptor-mediated
facilitation of adenosine uptake by studying the effect of
CGS 21680 in the presence and in the absence of protein
kinases inhibitors. We also compared the effect of CGS
21680 on [3H]adenosine uptake with those of the cAMP
analogue, dbcAMP (0.1 mM) and the PKC activator, PDD
(250 nM; Castagna et al. 1982). In this new set of experi-
ments, synaptosomes took up 0.30 ± 0.06 pmol of
[3H]adenosine per mg of protein (n ¼ 7) in a control
situation. Figure 2 shows that, as before, CGS 21680
(30 nM) enhanced the amount of [3H]adenosine retained by
the synaptosomes by 122 ± 34% (n ¼ 6, p < 0.05). How-
ever, when CGS 21680 (30 nM) was added in the presence of
the PKC inhibitor, GF-109203X (1 lM; Toullec et al. 1991),
the A2A receptor-mediated facilitation of [
3H]adenosine
uptake was fully prevented (p < 0.05 as compared to CGS
21680 alone, n ¼ 4). Furthermore, direct PKC activation
with PDD (250 nM) also increased [3H]adenosine uptake by
128 ± 41% (n ¼ 4, p < 0.05), mimicking the effect of CGS
21680 (30 nM). On the other hand, the PKA selective
inhibitor H-89 (1 lM; Chijiwa et al. 1990), failed to signi-
ficantly modify the facilitatory effect of CGS 21680 on
[3H]adenosine uptake (n ¼ 5, p > 0.05). The enhancement of
cAMP levels with dbcAMP (0.1 mM) also did not signifi-
cantly increase [3H]adenosine uptake (n ¼ 6, p > 0.05;
Fig. 1). When applied in the absence of CGS 21680, neither
H-89 (1 lM) nor GF-109203X (1 lM), significantly modified
[3H]adenosine uptake (n ¼ 3–4, p > 0.05).
Activation of A2A receptor enhances adenosine release
The observation that the activation of A2A receptors
enhanced the uptake of adenosine does not allow to
discriminate between the possibilities that A2A receptor
activation was either directly interfering with the activity of
nucleoside transporters or indirectly conditioning their func-
tion by modifying the gradient of adenosine across the
plasma membrane, i.e. changing intrasynaptosomal metabo-
lism (see e.g. Hammer et al. 2001). To check the first
possibility we took advantage of the bi-directionality of the
nucleoside transporters, and evaluated if the activation of
A2A receptors would modulate the release of adenosine from
hippocampal nerve terminals. Figure 3 shows that CGS
21680 (30 nM) significantly (n ¼ 6, p < 0.05) increased by
91 ± 12% the extracellular accumulation of adenosine
evoked by a pulse of high potassium, when compared to
the same depolarizing conditions in the absence of CGS
21680. This effect was totally prevented by the selective A2A
receptor antagonist, ZM 241385 (50 nM).
Under the experimental conditions used, the evoked-
release of adenosine was in great part due to the activity of
ENTs as the inhibitors of nucleoside transporters, NBTI
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Fig. 1 Effect of A1 and A2A receptor activation on [
3H]adenosine
(1 lM) uptake by hippocampal nerve terminals. A total of 100% in the
ordinates represents the amount of [3H]adenosine taken up in control
conditions (0.27 ± 0.06 pmol). Drugs added to the incubation medium
are indicated below each bar. Data are mean ± SEM. Note that the A2A
receptor agonist CGS 21680 (30 nM) increased [3H]adenosine uptake
(n ¼ 7), an effect prevented by the A2A antagonist SCH
58261(250 nM; n ¼ 7). On the other hand, the A1 receptor agonist,
CPA (100 nM), did not modify (n ¼ 6, p >0.05) [3H]adenosine uptake
by hippocampal synaptosomes. When applied in the absence of CGS
21680, SCH 58261 (250 nM) did not significantly modify (n ¼ 6,
p >0.05) [3H]adenosine uptake. *p < 0.05 as compared to control,
**p < 0.05 as compared to the effect of CGS 21680 (30 nM) alone.
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Fig. 2 Influence of PKA and PKC activities upon adenosine uptake
and its modulation by A2A receptor activation. A total of 100% in the
ordinates represents the amount of [3H]adenosine taken up in control
conditions (0.30 ± 0.06 pmol). Synaptosomes pre-incubation for
10 min with the PKC inhibitor, GF-109203X (1 lM), fully prevented the
CGS 21680-induced facilitation of [3H]adenosine uptake (n ¼ 4).
Furthermore, PKC activation with phorbol-12–13-didecanoate (PDD,
250 nM) mimicked the CGS 21680-induced facilitation of [3H]adeno-
sine uptake (n ¼ 4, p < 0.05). On the other hand, synaptosomes pre-
incubation for 10 min with the selective PKA inhibitor, H-89 (1 lM), did
not modify the facilitatory effect of CGS 21680 (30 nM; n ¼ 5). Also,
the enhancement of cAMP levels with dbcAMP (0.1 mM) did not sig-
nificantly increase [3H]adenosine uptake (n ¼ 6). Neither H-89 (1 lM)
nor GF-109203X (1 lM), when applied in the absence of CGS 21680,
significantly modified (n ¼ 3–4, p > 0.05) [3H]adenosine uptake (not
shown in the Figure). *p < 0.05 as compared to control, ** p < 0.05 as
compared to the effect of CGS 21680 (30 nM) alone.
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(10 lM) plus dipyridamol (20 lM), reduced the evoked
release of adenosine by 63 ± 9% (n ¼ 3, p < 0.05).
Furthermore, the ability of A2A receptors to facilitate the
evoked release of adenosine from nerve terminals was also
significantly attenuated (69 ± 18%, n ¼ 4, p < 0.05) in the
presence of dipyridamol (20 lM) plus NBTI (10 lM),
indicating that the facilitatory effect of CGS 21680 mostly
depends on the activity of ENTs.
Differential modulation of [3H]ACh by adenosine release
under two stimulation paradigms: an example of the
functional relevance of the activation of ENTs by A2A
receptors
To evaluate the potential implications of the control of ENTs
by A2A receptor activation, we investigated a functional
situation in which the control of nucleoside transporters by
A2A receptors could crucially affect adenosine neuromodu-
lation. We hypothesized that the well-known A1 receptor-
mediated tonic inhibition of [3H]ACh-evoked release could
be affected if the stimulation protocol was changed from
LFS to HFS conditions. Indeed, HFS paradigms favour A2A
receptor activation by endogenous adenosine (Correia-de-Sa
et al. 1996), and any influence of A2A receptor activation
upon the transport of adenosine across the plasma membrane
should result in differences in the modulation of evoked
[3H]ACh release by endogenous adenosine. We performed
these experiments in the CA3 area of the hippocampus
because it was previously shown that, in this area, endog-
enous adenosine tonically activates both inhibitory-A1 and
facilitatory-A2A receptors, with the overall effect being a tonic
inhibition of [3H]ACh release (Cunha et al. 1994).
The relative amount of tritium released after depolarizing
the subslices with either LFS (2 Hz, 2 min) or HFS (four
bursts of 60 pulses at 50 Hz, with an interburst interval of
200 ms) was similar for both stimulation paradigms
(Fig. 4a). As expected, the selective A1 receptor antagonist,
DPCPX (250 nM; Cunha et al. 1994), facilitated the release
of [3H]ACh triggered by LFS (14.5 ± 2.8% increase; n ¼ 4,
p < 0.05). In contrast, when CA3 hippocampal subslices
were stimulated with the HFS paradigm, DPCPX (250 nM)
failed significantly (n ¼ 5, p > 0.05) to modify the evoked
release of [3H]ACh (Fig. 4b). To avoid the feed-forward
inhibition of ecto-5¢-nucleotidase by ATP released during
stimulation (e.g. James and Richardson 1993), which could
occlude endogenous neuromodulation by adenosine during
HFS trains, we performed experiments in which the CA3
hippocampal subslices were also stimulated at 50 Hz (five
bursts of 150 pulses for 3 s; total number of pulses 240, as
for the LFS) but with longer (17 s) interburst intervals
(HFSL). This protocol might temporally bypass inhibition of
ecto-5¢-nucleotidase and create conditions for the formation
of adenosine from released adenine nucleotides (see Correia-
de-Sa´ et al. 1996). However, under this HFSL protocol,
DPCPX (250 nM) also failed to modify (n ¼ 5, p > 0.05) the
evoked release of [3H]ACh.
This modification of the effect of DPCPX on [3H]ACh
release according to the frequency of stimulation could be
due to: (i) a modification of the source and/or metabolism of
released adenosine available to activate A1 receptors or (ii) to
a desensitization and/or modification of efficacy of A1
receptors. To distinguish between these two possibilities, we
directly activated A1 receptors with its selective agonist,
CPA. The evoked release of [3H]ACh under both paradigms
of stimulation was inhibited by CPA (300 nM) in a similar
manner (LFS: 26.3 ± 1.8% inhibition, n ¼ 3; HFS:
23.2 ± 2.9% inhibition, n ¼ 3), which seems to exclude
the hypothesis of occurring a HFS-induced desensitization of
A1 receptors and favours the possibility of existing a different
extracellular metabolism of adenosine reaching A1 receptors
under HFS.
Our first working hypothesis predicted that HFS would
trigger a preferential formation of ATP-derived adenosine,
potentiating A2A receptor activation and enhancing the
uptake activity of nucleoside transporters, thus largely
decreasing A1 receptor tonic activation. Some readily testable
strings of this hypothesis were considered: (i) the blockade of
nucleoside transporters would allow a greater accumulation
of adenosine, which would now be able to activate A1
receptors; (ii) the blockade of A2A receptors would prevent
the enhancement of nucleoside transporters efficiency and
hence adenosine would accumulate and activate A1 recep-
tors. As predicted, upon blockade of ENTs with NBTI
(10 lM, present in S1 and S2), DPCPX (250 nM, added
before S2) was now able to increase by 15.6 ± 0.9% (n ¼ 5,
p < 0.05) the evoked release of [3H]ACh triggered by HFS,
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Fig. 3 Time course of the outflow of adenosine from superfused hip-
pocampal nerve terminals stimulated with KCl (28 mM) for 5 min as
indicated by the bar above the abscissa. A2A receptor agonist CGS
21680 (30 nM; d), or a combination of both CGS 21680 (30 nM) and
the A2A receptor antagonist, ZM 241385 (20 nM; r) were added
10 min before starting sample collection. Each point is mean ± SEM.
Note that CGS 21680 (30 nM) increased the evoked outflow of
adenosine (d), as compared to control conditions (s; n ¼ 7, p < 0.05),
an effect prevented by ZM 241385 (30 nM; r; n ¼ 4, p < 0.05).
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in marked contrast with the lack of effect of DPCPX
(250 nM) in the absence of the adenosine transport inhibitor
(Fig. 5). Using the LFS paradigm, no significant (n ¼ 3,
p > 0.05) differences in the DPCPX-induced facilitation of
[3H]ACh-evoked release were encountered when looking at
its effects in the absence or in presence of NBTI (10 lM;
Fig. 5). We then tested if the blockade of A2A receptor
would increase A1 receptor-mediated tonic inhibition of
[3H]ACh-evoked release. Also as predicted, in the presence
of SCH 58261 (250 nM, present in S1 and S2), DPCPX
(250 nM, added before S2) significantly (n ¼ 4, p < 0.05)
increased HFS-evoked [3H]ACh release by 32.7 ± 10.0%, in
marked contrast with the lack of effect of DPCPX (250 nM)
in the absence of the A2A receptor antagonist (Fig. 6). SCH
58261 (250 nM) also tended to increase the effects of DPCPX
(250 nM) under LFS stimulation but this did not reach
statistical significance (n ¼ 4, p > 0.05; Fig. 5).
From the results shown in Figs 5 and 6 it also emerged
that the action of DPCPX upon HFS and LFS is similar,
providing that adenosine transporters are inhibited (Fig. 5,
2nd and 4th bar) or A2A receptors blocked (Fig. 6, 2nd and
4th bar).
Discussion
The main finding of the present work was that A2A receptors
enhance the activity of nucleoside transporters in rat
hippocampal nerve terminals. Thus, activation of A2A
receptors with their selective agonist, CGS 21680, facilitated
the uptake of adenosine and enhanced the evoked release of
adenosine, which points to a direct effect of A2A receptors on
nucleoside transporters, rather than an indirect action result-
ing from a modification of the adenosine gradient of
concentrations across the plasma membrane (i.e. metabolic
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Fig. 5 Effect of the nucleoside transport blocker, NBTI (10 lM) on the
facilitation caused by the selective A1 antagonist, DPCPX (250 nM), of
the evoked release of [3H]ACh under high-frequency-stimulation
(HFS: four bursts of 1.2 s at 50 Hz, separated by 200 ms) and low-
frequency-stimulation (LFS, 2 Hz, 2 min) paradigms. The absence (–)
or presence (+) of NBTI (10 lM) is indicated below each bar. NBTI
(10 lM) was added before starting sample collection and was present
thereafter during S1 and S2; DPCPX (250 nM) was added 15 min
before S2. The action of DPCPX in the presence of NBTI (+) was
calculated by comparing the S2/S1 ratio obtained in the same
experiments in parallel chambers where only NBTI was added. The
effect of DPCPX in the absence of NBTI (–) was calculated by taking
as control the S2/S1 ratios obtained in the same experiments in par-
allel chambers with no added drugs. Note that the presence of NBTI
(10 lM) enhanced the facilitatory effect of DPCPX (250 nM), under
HFS (n ¼ 5, *p < 0.05) but not under LFS (n ¼ 3, p > 0.05), as
compared to the absence of NBTI. Each bar is mean ± SEM.
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Fig. 4 [3H]ACh release under high-frequency stimulation (HFS: four
bursts of 1.2 s at 50 Hz, separated by 200 ms) and low-frequency
stimulation (LFS: 2 Hz, 2 min) in the absence and in the presence of
the A1 selective antagonist, DPCPX (250 nM). (a) Time course of the
tritium outflow from hippocampal slices under LFS (s) and under HFS
(d) in control conditions, i.e. in the absence of drugs. Fractional
release is the relative amount of tritium present in each collected
sample in comparison to the total amount of tritium present in the
tissue at the time of sample collection. The stimulation periods, S1 and
S2, were applied at min 6 (S1) and min 36 (S2). Note that the relative
amount of tritium released after stimulation is similar for both stimu-
lation paradigms. The S2/S1 ratios obtained under HFS (1.15 ± 0.02,
n ¼ 8) and LFS (1.12 ± 0.04, n ¼ 7) were also not significantly dif-
ferent (p > 0.05). Each point is mean ± SEM (b) Comparison of the
facilitatory effect of the selective A1 receptor antagonist, DPCPX
(250 nM), on the field electrically evoked release of [3H]ACh from CA3
hippocampal slices under LFS and HFS, as indicated below each bar.
DPCPX (250 nM) application 15 min before S2 significantly increased
the S2/S1 ratios under LFS (n ¼ 4, p < 0.05), but not under HFS (n ¼
5, p > 0.05). As indicated (*p < 0.05), the effects of DPCPX under
both stimulation paradigms were statistically different. Each bar is
mean ± SEM.
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effect). Furthermore, as for the exogenously added A2A
receptor agonist, endogenous adenosine released upon HFS
was able to activate A2A receptors and enhance the activity of
nucleoside transporters. The main consequence of this A2A
receptor-mediated enhancement of the activity of nucleoside
transporters was the marked reduction of the tonic activation
of inhibitory A1 receptors upon high-frequency firing. This
modulatory action of A2A receptors on the activity of the
adenosine transporters constitutes a clear demonstration that
a neuromodulatory receptor is able to control the extracel-
lular levels of its endogenous ligand and, hence, to influence
its ability to control neurotransmitter release.
Nucleoside transporters are a family of membrane proteins
with different pharmacological and kinetic properties that
have in common their ability to transport nucleosides,
namely adenosine, through the plasma membrane (reviewed
in Cabrita et al. 2002). Two main groups of nucleoside
transporters have been identified: (i) concentrative transport-
ers (CNTs; Gray et al. 2004), which use sodium gradient to
transport nucleosides against their concentration gradient and
(ii) equilibrative bi-directional transporters (ENTs; Baldwin
et al. 2004). Low nanomolar concentrations (50 nM) of
NBTI block the ENT1 subtype (also called es from
equilibrative-sensitive), whereas blockade of the equilibra-
tive insensitive (ei) ENT2 subtype is attained with micro-
molar (10 lM) concentrations of NBTI or dipyridamole
(Archer et al. 2004). Therefore, in our experimental condi-
tions, the NBTI (10 lM)-sensitive adenosine uptake and
release might occur through ENTs, either of the ENT1 or
ENT2 subtypes, which are widely expressed in the brain,
including in hippocampal neurones (Anderson et al. 1999a,
1999b) and play the major role in controlling the extracel-
lular levels of adenosine in neuronal cells. Evidence for
moderate levels of CNT2 transcripts in adult rat brain
including hippocampal neurones has been recently reported
(Guille´n-Go´mez et al. 2004). It was also recently shown that
the activity of CNT2 in non-excitable cells is enhanced by
activation of A1 receptors (Duflot et al. 2004), which in our
experimental conditions did not influence adenosine uptake
by nerve terminals. The relative contribution, if any, of CNTs
for adenosine transport in the hippocampus and how they are
regulated by selective activation of adenosine receptors
remains to be investigated and is outside the scope of the
present work.
In spite of the evidence available to support a predominant
role of ENTs in controlling the levels of extracellular
adenosine in the nervous system, little is known about the
modulation of the activity of ENTs. They are known to
display a peculiar mnemonic-like activity (Casillas et al.
1993) and some evidence has been gathered indicating that
their activity can be modulated by G proteins (Sweeney
1996) and protein kinases (Sen et al. 1999). A2A receptors
are coupled to several G proteins and their activation
influences at least the activities of two types of protein
kinases, PKA and PKC. The findings that a PKC inhibitor,
but not a PKA inhibitor, prevents the enhancement of
adenosine transport induced by the A2A receptor agonist, and
that PKC activators per se influence adenosine transport in a
similar way to CGS 21680, suggest that A2A receptors
control ENTs activity in a PKC-dependent manner.
The function of A2A receptors in the hippocampus still
remains controversial. In fact, the most evident role of
endogenous extracellular adenosine in the hippocampus is an
inhibition of synaptic transmission and neuronal excitability
through the activation of the more abundant A1 receptors
(reviewed in Dunwiddie and Masino 2001). However, the
activation of A2A receptors causes a discrete facilitation of
synaptic transmission and neurotransmitter release, which is
in part due to their ability to decrease A1 receptor function
(Lopes et al. 2002). Also, A2A receptors effectively control,
in a permissive manner, the action of other neuromodulatory
systems, leading to the proposal that A2A receptors are
mostly devoted to the fine-tuning of other neuromodulatory
systems, rather than to directly controlling the release of
neurotransmitters (Sebastia˜o and Ribeiro 2000). The current
observation that A2A receptors can also control the activity of
ENTs further widens the scope of the potential impact of A2A
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Fig. 6 Effect of the A2A receptor agonist, SCH 58261 (250 nM) on the
facilitation caused by the selective A1 antagonist, DPCPX (250 nM), of
the evoked release of [3H]ACh under high-frequency-stimulation
(HFS: four bursts of 1.2 s at 50 Hz, separated by 200 ms) and low-
frequency-stimulation (LFS, 2 Hz, 2 min) paradigms. The absence or
presence of SCH 58261 (250 nM) is indicated below each bar. SCH
58261 (250 nM) was added before starting sample collection and was
present thereafter during S1 and S2; DPCPX (250 nM) was added
15 min before S2. The action of DPCPX in the presence of SCH 58261
(+) was calculated by comparing the S2/S1 ratio obtained in the same
experiments in parallel chambers where only SCH 58261 was present.
The effect of DPCPX in the absence of SCH 58261 (–) was calculated
by taking as control the S2/S1 ratios obtained in the same experiments
in parallel chambers with no added drugs. Note that the presence of
SCH 58261 (250 nM) significantly increased the facilitatory effect of
DPCPX (250 nM) under HFS (n ¼ 4, *p < 0.05) but not under LFS
(n ¼ 4, p >0.05), as compared to the absence of SCH 58261. Each
bar is mean ± SEM.
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receptors in controlling the function of nerve terminals and
challenges further investigations on other cell types in the
brain that also possess A2A receptors and ENTs, such as
microglia (e.g. Ku¨st et al. 1999; Hong et al. 2000) and
astrocytes (e.g. Gu et al. 1996; Nishizaki et al. 2002).
Interestingly, the fine-tuning neuromodulatory actions medi-
ated by A2A receptor activation may involve the PKA/cAMP
transducing system (e.g. Dio´genes et al. 2004) but in some
cases, as observed in the present work, may be independent
of PKA and involve PKC (e.g. Lopes et al. 2002).
One important aspect in the realm of the physiological
function of the observed modulation of ENTs activity by A2A
receptor activation is to understand if this will lead to a
greater ability to release or remove synaptic adenosine. In
fact, the seminal work of Geiger’s group has clearly
established the bi-directional activity of ENTs (see Gu et al.
1995). When studying the release of adenosine from nerve
terminals, inhibition of ENTs decreases the evoked release of
adenosine (MacDonald and White 1985), which indicates
that, at least in these structures, ENTs contribute to the
release of the nucleoside. Nonetheless, in more integrated
preparations, such as electrically stimulated brain slices, it is
most commonly observed that inhibitors of ENTs actually
enhance the extracellular levels of adenosine (reviewed in
Latini and Pedata 2001), implying that the net result of ENT
activity is to take up the nucleoside. Indeed, extracellular
adenosine concentrations are usually higher than the intra-
cellular ones because (i) neuronal stimulation leads to the
release of adenine nucleotides that are converted to
adenosine through the ecto-nucleotidase pathway (see
Zimmermann 2000) and (ii) cytoplasmatic adenosine is
quickly converted into AMP, through adenosine kinase (see
e.g. Latini and Pedata 2001), which may further favour the
uptake of adenosine in order to re-equilibrate its gradient
across the cell membrane. In accordance with the predom-
inant role of ENTs to take up, rather than to release,
adenosine in hippocampal preparations, one should expect
that the A2A receptor-mediated enhancement of the activity
of ENTs would result in an enhancement of the uptake of
extracellular adenosine and therefore, to a lower degree of
tonic activation of the predominant adenosine receptors in
the hippocampus, the A1 inhibitory receptors. This was
directly confirmed when comparing adenosine modulation of
the electrically evoked release of ACh at high and low
frequencies of stimulation.
The different patterns of adenosine modulation of ACh-
evoked release according to the frequency of stimulation
observed in the present work, may be combined with what is
known about frequency–dependency of adenosine metabo-
lism, as summarized in Fig. 7. Upon HFS of hippocampal
preparations, there is a predominant release of ATP and a
predominant formation of adenosine from this released ATP
(Cunha et al. 1996b). Thus, under conditions of HFS it is
expected that the gradient of adenosine concentrations across
the plasma membrane will direct ENTs to take up adenosine.
Also, it was previously shown that ATP-derived adenosine
preferentially activates A2A receptors (Cunha et al. 1996a)
and, consequently, stimulation at high frequencies leads to a
preferential activation of A2A receptors. This is consistent
with the hypothesis displayed in Fig. 7(b) that the greater
activation of A2A receptors by the increased formation of
ATP-derived adenosine upon HFS might be increasing the
activity of nucleoside transporters to avoid a spread of
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Fig. 7 Model for the role of A2A receptors in the modulation of synaptic
adenosine levels. Upon low frequency stimulation (a), the build-up of
extracellular adenosine is moderate and dependent on both ENT’s
activity and the ecto-5¢-nucleotidase (5¢-N) pathway derived adeno-
sine. In these conditions adenosine reaches A1 receptors in the active
zone, resulting in a tonic inhibitory effect of neurotransmitter (NT)
release. During high frequency stimulation (b) the increased formation
of ATP-derived adenosine leads to a greater activation of A2A recep-
tors that in turn increase the activity of nucleoside transporters to avoid
a spread of extracellular adenosine, limiting its availability to activate
A1 receptors.
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extracellular adenosine sufficient to activate A1 receptors.
This means that there is a tight interplay between the
extracellular metabolism of adenosine and the activation of
adenosine receptors in the synaptic cleft to define the
outcome of adenosine neuromodulation. Accordingly, under
low-frequency firing there is a moderate build-up of extra-
cellular adenosine that reach A1 receptors because of the
moderate activity of ENTs to take up adenosine (Fig. 7a).
This hypothetical scenario, which successfully explains the
data observed, takes into account the tight association
between ecto-nucleotidases, namely ecto-5¢-nucleotidase,
and A2A receptors (Cunha et al. 1996a; Napieralski et al.
2003) and re-enforces the likely close association of A1
receptors with ENTs. However, it is obviously based on some
key concepts that await experimental confirmation. Namely,
it assumes that the different players involved in adenosine
neuromodulation have a highly organized localization in a
synapse and that there is a gradient of synaptic adenosine
concentrations that varies according to the site of formation
and removal of adenosine from the synapse.
In conclusion, the present work indicates that synaptic A2A
receptors in the hippocampus enhance the activity of ENTs.
The study of the evoked release of ACh at different
frequencies of stimulation allowed documenting a physiolo-
gical situation where this A2A receptor-mediated enhance-
ment of ENTs activity plays a pivotal role in re-setting
adenosine neuromodulation. Overall, these findings show a
close interplay between adenosine production/inactivation
and the activity of adenosine receptors to define adenosine
neuromodulation.
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